Publications
Capturing the lived experiences of informal care in acute leukemia
20 November 2025
Providing informal care to someone living with acute leukemia imposes a severe multidimensional burden, reshaping relationships and affecting mental health, physical health, career, finances, social activities and more.
The commercial case for investing in ALS
13 November 2025
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and economic consequences.
Achieving Accelerated Patient Access to Cancer Care in Europe
3 November 2025
OHE developed the Accelerated Patient Access to Cancer Care in Europe (APACE) framework through a structured, multidisciplinary stakeholder engagement process.
Patient preferences for treatment in relapsed/refractory acute leukemia
23 October 2025
When acute leukemia relapses, treatment decisions can be complex. Patients may face trade-offs between survival benefits, side effects and how treatment is delivered. This study asked people with acute leukemia across five countries what matters most to them when making these choices.
The value of cell and gene therapies to the UK economy
20 October 2025
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to routine care: more than thirty products are already licensed worldwide and over two thousand are in clinical development.
The broader economic benefits of COVID-19 vaccination
13 October 2025
Extending COVID-19 vaccination eligibility to working-age adults could nearly triple the benefits to national economies.
Understanding the preferences of people with acute leukemia for different health outcomes
25 September 2025
When we want to understand or measure someone’s “health-related quality-of-life”, we typically ask them to describe the problems they have with different aspects of their health. In this study, we wanted to understand which aspects, or “dimensions”, of health-related quality-of-life are most important to the general public and to persons with acute leukemia.
Taking STRIDES: The value of diagnostics against AMR
10 June 2025
Addressing a critical gap in AMR policy and evaluation Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to 10 million deaths annually…
Altering the trajectory of HIV in Europe
22 May 2025
Despite substantial medical advancements that have transformed HIV into a manageable chronic condition for individuals, the epidemic remains a pressing public health concern in Europe.